United States - English - NLM (National Library of Medicine)

accord healthcare inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: - motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. - autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse, and respiration rate. - apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. - vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling "on edge," irritability, impatience. the above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. however, mild depressive symptoms are common in gad. the effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad. however, in a study of long-term use, 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect. therefore, the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient. buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. the use of monoamine oxidase inhibitors (maois) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. the use of buspirone within 14 days of stopping an maoi intended to treat depression is also contraindicated. starting buspirone in a patient who is being treated with reversible maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome. (see warnings, dosage and administrationand drug interactions) buspirone hydrochloride is not a controlled substance. in human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence. human volunteers with a history of recreational drug or alcohol usage were studied in two double-blind clinical investigations. none of the subjects were able to distinguish between buspirone hydrochloride tablets and placebo. by contrast, subjects showed a statistically significant preference for methaqualone and diazepam. studies in monkeys, mice, and rats have indicated that buspirone lacks potential for abuse. following chronic administration in the rat, abrupt withdrawal of buspirone did not result in the loss of body weight commonly observed with substances that cause physical dependency. although there is no direct evidence that buspirone hydrochloride tablets causes physical dependence or drug-seeking behavior, it is difficult to predict from experiments the extent to which a cns-active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone hydrochloride tablets misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - acyclovir - suspension - 200 mg/5 ml - acyclovir 200 mg/5 ml

Kenya - English - Pharmacy and Poisons Board

lincoln pharmaceuticals ltd c/o medox… 10, 12, 13, trimul estate, khatraj, taluka: - albendazole suspension 200 mg/5 ml - syrup - albendazole usp 200 mg/5 ml - antinematodal anthelmintic agents:

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: lecithin; sodium citrate dihydrate; colloidal anhydrous silica; xanthan gum; methyl hydroxybenzoate; aspartame; sorbitol; citric acid; flavour - alcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,alcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: sorbitol; sodium citrate dihydrate; citric acid; colloidal anhydrous silica; lecithin; aspartame; xanthan gum; methyl hydroxybenzoate; flavour - mycocell is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycocell is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: sorbitol; sodium citrate dihydrate; citric acid; methyl hydroxybenzoate; xanthan gum; aspartame; lecithin; colloidal anhydrous silica; flavour - pharmacor mycophenolate is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,pharmacor mycophenolate is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - azithromycin oral suspension 200 mg / 5 ml - oral suspension - each 5 ml contain : azithromycin usp _..200 mg … - antibacterials for systemic use: macrolides

Kenya - English - Pharmacy and Poisons Board

macleods pharmaceuticals limited atlanta arcade church road near leela hotel - nevirapine tablets usp 200 mg - tablet - nevirapine usp... 200 mg - antivirals for systemic use: non-nucleoside

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - nevirapine tablets usp 200mg - tablet - nevirapine usp - 200mg - antivirals for systemic use: non-nucleoside

United States - English - NLM (National Library of Medicine)

direct rx - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 month continual du